The global amyloidosis therapeutics market size will grow by USD 357.22 million during 2019-2023. This market report provides a detailed analysis of the market by type (systemic amyloidosis and other amyloidosis) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on many market vendors, including AbbVie Inc., Allergan Plc, Alnylam Pharmaceuticals Inc., Amgen Inc., Celgene Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Key Insights on Amyloidosis Therapeutics Market - Global Forecast 2019-2023
Browse TOC and LoE with selected illustrations and example pages of on amyloidosis therapeutics market
Request a FREE sample now!
Industry Overview
Amyloidosis is a rare disease, and the amyloidosis therapeutics market has only three approved drugs. As a result, there is a significant unmet need for treatment providing potential business opportunities to vendors. Moreover, as the prevalence of the condition increases with age, the rising geriatric population is augmenting the need for effective therapeutics. Considering these factors, the market has been recording extensive R&D of novel therapies. Many organizations, such as Vasculitis Foundation and National Organization for Rare Disorders, have been providing research funding to small or mid-sized companies to complete their clinical trials and launch drugs.
The three approved drugs available in the amyloidosis market and the therapeutic candidates (under development) have been awarded special drug designations by regulatory bodies such as the US FDA and EMA. The designations include breakthrough drug designation and orphan drug designation. The sponsors of these drugs receive various incentives and tax benefits, encouraging vendors to expedite R&D on new molecules. This will support amyloidosis treatment market growth during the forecast period. As a result of these factors, the market will register a CAGR of almost 8% during 2019-2023.
Top Companies in Amyloidosis Therapeutics Market
The global market is fragmented. To help clients improve their market positions, this amyloidosis therapeutics market forecast report provides an analysis of the market’s competitive landscape and offers information on the drugs offered by various companies. The report also includes information on the upcoming amyloidosis treatment trends and challenges that will influence market growth. This will help companies in creating strategies to make the most of future growth opportunities.
The report offers a detailed analysis of several leading amyloidosis drugs manufacturers, including:
- AbbVie Inc.
- Allergan Plc
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Celgene Corp.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals Inc.
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
Market Segmentation
Amyloidosis Therapeutics Market by Type
- Systemic amyloidosis
- Other amyloidosis
The systemic amyloidosis segment held the largest market share in 2018. The high prevalence of the condition, recent drug approvals, and growing geriatric population will boost the growth of the systemic amyloidosis market segment during the forthcoming years. This report provides an accurate prediction of the contribution of all the segments to the growth of the amyloidosis therapeutics market size.
Amyloidosis Therapeutics Market by Region
- Asia
- Europe
- North America
- ROW
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest amyloidosis therapeutics market share throughout the forecast period. The sales of off-label drugs, increasing prevalence of subtypes of amyloidosis, and growing geriatric population are contributing to the amyloidosis therapeutics industry growth in the region.
Major Highlights of the Amyloidosis Therapeutics Market - Global Forecast 2019-2023
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the amyloidosis therapeutics market during the next five years
- Precise estimation of the global amyloidosis therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the amyloidosis therapeutics industry Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details of factors that will challenge the growth of amyloidosis therapeutics companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1 Preface
- 2.2 Preface
- 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Systemic amyloidosis - Market size and forecast 2018-2023
- Other amyloidosis - Market size and forecast 2018-2023
- Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 12: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie Inc.
- Allergan Plc
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Celgene Corp.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals Inc.
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
PART 13: APPENDIX
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
PART 14: EXPLORE TECHNAVIO